Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Lepidico

    MCap

    AUD107m

    Last close

    AUD0.02

    ▲ 0.01 (100.00%)

    Silver Spruce Resources

    MCap

    CAD5m

    Last close

    CAD0.03

    ▲ 0.01 (50.00%)

    Context Therapeutics

    MCap

    USD16m

    Last close

    USD1.00

    ▲ 0.32 (47.06%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

Onxeo (EU: ONXEO)

Currency in EUR

Last close As at 06/02/2023

EUR0.33

▲ −0.01 (−2.94%)

Market capitalisation

EUR37m

Latest Insights

View More

Healthcare

Onxeo – Edison Open House interview

Healthcare

Onxeo – executive interview

Healthcare

Onxeo — Progress with both REVOCAN and DRIIV-1b trials

Healthcare

Onxeo — Expanding AsiDNA R&D programme
Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (€m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 1.7 (3.4) (41.5)
Relative (6.8) (6.6) (38.8)
52 week high/low €0.6/€0.3

Financials

Edison Investment Research is terminating coverage on Steakholder Foods (formerly known as MeaTech) (MITC), Mesoblast (MSB), Bluglass (BLG), InMed Pharmaceuticals (INM), Onxeo (ONXEO), Arcane Crypto (ARCANE) and Aberdeen Diversified Income and Growth Trust (ADIG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2019A 4.3 (9.1) (11.5) (14.98) N/A N/A
2020A 1.8 (7.2) (8.2) (12.26) N/A N/A
2021E N/A N/A N/A N/A N/A N/A
2022E N/A N/A N/A N/A N/A N/A

Research

View All

More from our Healthcare team

Healthcare

DNA damage repair inhibitors

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

sromanoff@edisongroup.com 020 3077 5700
Read latest

Thematics

View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free